Method for treating cholangiocarcinoma having PTEN gene mutation and / or deletion
WO2025124411A1PCT designated stage expired Publication Date: 2025-06-19JIANGSU CHIA TAI FENGHAI PHARMA CO LTD +1
Patent Information
- Application Number
- PCT/CN2024/138331
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-12
- Filing Date
- 2024-12-11
- Publication Date
- 2025-06-19
Smart Images
Figure CN2024138331_19062025_PF_FP_ABST
Abstract
A method for treating cholangiocarcinoma having PTEN gene mutation and / or deletion, which method specifically comprises administering, to a patient with cholangiocarcinoma, a therapeutically effective amount of a proteasome inhibitor as shown in formula (I) or formula (II) or a pharmaceutically acceptable salt thereof. Preferably, the cholangiocarcinoma is cholangiocarcinoma having PTEN gene mutation and / or deletion. The method overcomes the problem of an existing protease inhibitor having no therapeutic effect in the treatment of solid tumors due to drug distribution issues, and shows good efficacy in patients with cholangiocarcinoma, especially, cholangiocarcinoma caused by PTEN gene mutation and / or deletion.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Application of combination of proteasome inhibitor and cell autophagy activator in bile duct cancer treatment
CN105063196A
Dipeptide boric acid composed of carboxylic acid and alpha-amino acid as well as ester compound thereof, and preparation method and application of dipeptide boric acid and ester compound thereof
CN105732683A
Deuterated dipeptide boric acids or esters thereof, and synthetic methods and uses of the compounds
CN106916177A
Synthesis and application of peptide borate compound
CN115785137A
Fibroblast activating protein inhibitor compounds and
JP2008545661A